

23. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet*. 2000;356:2144-8.
24. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med*. 2008;178:218-224.
25. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. *N Engl J Med*. 2009;360:973-984.
26. Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. *New England Journal of Medicine*. 2009;360:985-993.
27. Pavord ID, Haldar P, Bradding P, et al. Mepolizumab in refractory eosinophilic asthma. *Thorax*. 2010;65:370.
28. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. *New England Journal of Medicine*. 2014;71:1198-1207.
29. Nair P, O'Byrne PM. Measuring Eosinophils to Make Treatment Decisions in Asthma. *Chest*. 2016;150:485-7.
30. Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? *Lancet Respir Med*. 2015;3:824-825.
31. Kostikas K, Brindicci C, Patalano F. Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. *Curr Drug Targets*. 2018;19:1882-1896.
32. Kroegel C, Liu MC, Hubbard WC, et al. Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: Surface phenotype, density heterogeneity, and prostanoid production. *J Allergy Clin Immunol*. 1994;93:725-734.
33. Prin L, Capron M, Tonnel AB, et al. Heterogeneity of human peripheral blood eosinophils: Variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. *Int Arch Allergy Immunol*. 1983;72:336-346.
34. Kuo HP, Yu TR, Yu CT. Hypodense eosinophil number relates to clinical severity, airway hyperresponsiveness and response to inhaled corticosteroids in asthmatic subjects. *European Respiratory Journal*. 1994;7:1452-1459.
35. Abdala Valencia H, Loffredo LF, Misharin A V, et al. Phenotypic plasticity and targeting of Siglec-FhighCD11c low eosinophils to the airway in a murine model of asthma. *Allergy: European Journal of Allergy and Clinical Immunology* 2016;71:267-271.
36. Matucci A, Nencini F, Maggiore G, et al. High proportion of inflammatory CD62L low eosinophils in blood and nasal polyps of severe asthma patients. *Clinical & Experimental Allergy*. 2023;53:78-87.
37. Kanda A, Yun Y, Bui D Van, et al. The multiple functions and subpopulations of eosinophils in tissues under steady-state and pathological conditions. *Allergology International*. 2021;70:9-18.
38. Shah K, Ignacio A, McCoy KD, et al. The emerging roles of eosinophils in mucosal homeostasis. *Mucosal Immunol*. 2020;13:574-583.
39. Al-Shaikly T, Murphy RC, Parker A, et al. Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma. *European Respiratory Journal*. 2022;60:2101865.
40. Fukuda T, Dunnette SL, Reed CE, et al. Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. *American Review of Respiratory Disease*. 1985;132:981-985.
41. Peters MS, Gleich GJ, Dunnette SL, et al. Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: A morphological basis of hypodense eosinophils. *Blood*. 1988;71:780-785.
42. Januskevicius A, Jurkeviciute E, Janulaityte I, et al. Blood Eosinophils Subtypes and Their Survivability in Asthma Patients. *Cells*. 2020;9:1248.
43. Van Hulst G, Jorssen J, Jacobs N, et al. Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma. *European Respiratory Journal*. 2022;59:2100935.
44. Novosad J, Krčmová I, Souček O, et al. Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment. *Int J Mol Sci*. 2023;24:5716.
45. Freeman CM, Curtis JL, Hastie AT. Finding the Right Biological: Eosinophil Subset Differences in Asthma and COPD. *Am J Respir Crit Care Med*. Epub ahead of print 13 June 2023. DOI: 10.1164/RCCM.202305-0811ED.
46. Cabrera López C, Sánchez Santos A, Lemes Castellano A, et al. Eosinophils Subtypes in Asthmatic and COPD Patients. *Am J Respir Crit Care Med*. Epub ahead of print 18 April 2023. DOI: 10.1164/rccm.202301-01490C.
47. Ijaz T, Pazdrak K, Kalita M, et al. Systems biology approaches to understanding Epithelial Mesenchymal Transition (EMT) in mucosal remodeling and signaling in asthma. *World Allergy Organ J*. 2014;7:13.
48. Denton E, Price DB, Tran TN, et al. Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. *Journal of Allergy and Clinical Immunology: In Practice* 2021;9:2680-2688.e7.
49. Chen M, Shepard K, Yang M, et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. *Clinical and Experimental Allergy*. 2021;51:546-555.
50. Corren J, Du E, Gubbi A, et al. Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma. *Journal of Allergy and Clinical Immunology: In Practice* 2021;9:1224-1231.e9.
51. Kroes JA, Zielhuis SW, van Roon EN, et al. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. *Biochem Pharmacol*. 2020;179:13978.
52. Rogliani P, Calzetta L, Matera MG, et al. Severe Asthma and Biological Therapy: When, Which, and for Whom. *Pulm Ther*. 2020;6:47-66.
53. Eger K, Kroes JA, ten Brinke A, et al. Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation. *J Allergy Clin Immunol. Pract* 2021;9:1194-1200.
54. McDowell PJ, Diver S, Yang F, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. *Lancet Respir Med*. 2021;9:1174-1184.
55. Poznanski SM, Mukherjee M, Zhao N, et al. Asthma exacerbations on benralizumab are largely non-eosinophilic. *Allergy: European Journal of Allergy and Clinical Immunology*. 2021;76:375-379.
56. Nair P, O'Byrne PM. Medical algorithms: Approach to adult asthma exacerbations. *Allergy*. 2021;76:3556-3559.
57. Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. *Journal of Allergy and Clinical Immunology*. 2020;145:75-65.
58. Menzies-Gow A, Szeffler SJ, Busse WW. The Relationship of Asthma Biologics to Remission for Asthma. *Journal of Allergy and Clinical Immunology: In Practice*. 2021;9:1090-1098.
59. Maglio A, Vitale C, Pelaia C, et al. Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5R: Results from a Multicenter Real-Life Study. *Int J Mol Sci*. 2023;24:2455.
60. Mengelers HJJ, Maikoe T, Hooibrink B, et al. Down modulation of L-Selection expression on eosinophils recovered from bronchoalveolar lavage fluid after allergen provocation. *Clinical and Experimental Allergy*. 1993;23:196-204.

Pro věrné čtenáře

Součástí Vnitřního lékařství 6/2023 je navíc supplementum
Zaznělo na XXXI. výročním sjezdu České kardiologické společnosti.

Najdete v něm přehledná shrnutí několika zajímavých bloků z jarního kongresu České kardiologické společnosti v Praze a Brně.

Věříme, že pro vás připomenutí této významné internistické akce bude přínosné.

